Bioequivalence, Food-Effect Assessment and Exploratory IVIVC of Two Extended-Release Tamsulosin 0.4 mg Formulations in Healthy Mexican Subjects
Pharmaceutics · 14.08.2026 · 18 (8) · 1008
DOI: 10.3390/pharmaceutics18081008 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 14.08.2026. Verfasst von Omar Emmanuel Hernández Piña und 5 weiteren Autor:innen. Beteiligte Einrichtung: Asofarma de México S.A. de C.V., Av. Santa Fe 485, Lomas de Santa Fe, Contadero, Cuajimalpa de Morelos, Mexico City C.P. 05348, Mexico. Die Arbeit nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Asofarma de México S.A. de C.V..
Abstract (Originalsprache)
Background/Objectives: Tamsulosin extended-release (ER) formulations minimize peak-related vasodilatory adverse events in benign prostatic hyperplasia (BPH) treatment. This study assessed the pharmacokinetics and bioequivalence of a generic tamsulosin 0.4 mg ER formulation against the innovator under fasting and fed conditions.
Methods
Two randomized, open-label, four-period crossover, single-dose trials were conducted in healthy Mexican males. Subjects received treatment following a 10 h fast or a high-fat meal, with a 7-day washout. Plasma tamsulosin was quantified over 72 h via LC-MS/MS. An exploratory in vitro–in vivo correlation (IVIVC) analysis was also performed.
Results
Analyses included 32 (fasting) and 58 (fed) subjects. In both states, 90% confidence intervals for Cmax, AUC0-t, and AUC0-∞ geometric mean ratios fell entirely within the 80.00–125.00% bioequivalence limits. The formulations showed comparable dissolution (f2 = 92.47), with numerical deconvolution proving most predictive in exploratory IVIVC. Notably, the pharmacokinetic profile of the test formulation was consistent with maintained controlled drug release under both dietary conditions and showed no pharmacokinetic evidence of food-induced dose dumping. Both formulations were well-tolerated; all adverse events were mild, with no clinically significant orthostatic hypotension observed.
Conclusions
The generic tamsulosin 0.4 mg ER formulation is bioequivalent to the reference product in both fasting and fed states. Its structural robustness prevents dose dumping, ensuring a favorable hemodynamic safety profile. Comparable dissolution and IVIVC findings further support their reliability in vivo performance and therapeutic interchangeability. ClinicalTrials.gov identifiers: NCT07698288 and NCT07698275.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Asofarma de México S.A. de C.V., Av. Santa Fe 485, Lomas de Santa Fe, Contadero, Cuajimalpa de Morelos, Mexico City C.P. 05348, Mexico.
- Escuela Superior de Medicina, Instituto Politécnico Nacional, Salvador Díaz Mirón, Esq. Plan de San Luis S/N, Casco de Santo Tomás, Miguel Hidalgo, Mexico City C.P. 11340, Mexico.
- Doctorado Institucional en Ingeniería y Ciencia de Materiales (DICIM), Universidad Autónoma de San Luis Potosí (UASLP), Av. Sierra Leona No. 550, Col. Lomas 2da. Sección, San Luis Potosí C.P. 78210, Mexico.
- Facultad de Ciencias Químicas, Universidad Autónoma de San Luis Potosí, Av. Dr. Manuel Nava No. 6, Zona Universitaria, San Luis Potosí C.P. 78210, Mexico.
ORCID-Profile: Alberto Martínez Muñoz, Abraham Escobedo-Moratilla, José Trinidad Pérez-Urizar
Förderung
- Asofarma de México S.A. de C.V.
Zitieren
APA
Hernández Piña, O. E., Martínez Muñoz, A., Guido Ávila, E. G., Escobedo-Moratilla, A., de la Cruz Cruz, P., & Pérez-Urizar, J. T. (2026). Bioequivalence, Food-Effect Assessment and Exploratory IVIVC of Two Extended-Release Tamsulosin 0.4 mg Formulations in Healthy Mexican Subjects. Pharmaceutics, 18(8), 1008. https://doi.org/10.3390/pharmaceutics18081008
Vancouver
Hernández Piña OE, Martínez Muñoz A, Guido Ávila EG, Escobedo-Moratilla A, de la Cruz Cruz P, Pérez-Urizar JT. Bioequivalence, Food-Effect Assessment and Exploratory IVIVC of Two Extended-Release Tamsulosin 0.4 mg Formulations in Healthy Mexican Subjects. Pharmaceutics. 2026;18(8):1008. doi:10.3390/pharmaceutics18081008
BibTeX
@article{HernndezPia2026,
author = {Hernández Piña, Omar Emmanuel and Martínez Muñoz, Alberto and Guido Ávila, Erika Gabriela and Escobedo-Moratilla, Abraham and de la Cruz Cruz, Porfirio and Pérez-Urizar, José Trinidad},
title = {Bioequivalence, Food-Effect Assessment and Exploratory IVIVC of Two Extended-Release Tamsulosin 0.4 mg Formulations in Healthy Mexican Subjects},
journal = {Pharmaceutics},
year = {2026},
volume = {18},
number = {8},
pages = {1008},
doi = {10.3390/pharmaceutics18081008}
}
EUVIMED